FMP
Diffusion Pharmaceuticals Inc.
DFFN
NASDAQ
Inactive Equity
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
4.4 USD
0.41 (9.32%)
About
ceo
Dr. Robert J. Cobuzzi Jr., Ph.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
CIK
0001053691
ISIN
US15713L1098
CUSIP
253748305
Address
300 East Main Street
Phone
434 220 0718
Country
US
Employee
13
IPO Date
May 23, 2008
Key Executives
